– Heather Kaiser was diagnosed with early-onset colon cancer at 42 and shares her journey through diagnosis, treatment, and life with cancer.
– Initially dismissed as hormonal or dietary issues, her symptoms eventually led to an emergency visit and a colonoscopy that found a large mass.
– As a mother of two young boys, her priority has been staying present for her family while navigating indefinite treatment.
Heather Kaiser is a 43-year-old attorney and mother of two who leads a busy life. In 2025, at age 42, she sought medical care for gastrointestinal symptoms. Her doctor initially attributed the problems to hormones or diet, and she went home feeling better and certain cancer was unlikely. When symptoms returned, she visited the emergency room and was again sent home, told it was “women’s issues.”
At a follow-up with her OB-GYN, her concerns were finally taken seriously and she was referred to a gastroenterologist. During a colonoscopy, a doctor found a mass “the size of a fist” and warned it would likely need surgical removal and was probably cancer. After pathology confirmed the diagnosis, Kaiser took a day to process the news before telling her family.
Surgery was scheduled for June 2025, about six months after her initial ER visit, timed so she could be there for her sons’ school year. The operation went as planned, but her surgeon suspected the margins weren’t clean, so she was referred to an oncologist and her tumor was sent for genetic testing. While waiting six weeks for biomarker results, a PET scan revealed extensive metastatic disease—spread to lymph nodes near the lungs and to the liver, an unusual pattern.
Biomarker testing showed Kaiser had a BRAF mutation, specifically V600E, a mutation seen in about 10% of metastatic colorectal cancers and typically associated with a poorer prognosis. At the time she learned the diagnosis, doctors estimated about a 13-month prognosis. Fortunately, clinical trials for the V600E mutation were available.
In August 2025, Kaiser joined a protocol related to the BREAKWATER clinical effort and became the first person in Minnesota to receive that protocol outside the original trial. She joked about calling herself “Patient Zero.” Her treatment combined four drugs—three intravenous and one oral medication, Braftovi. Prior to Braftovi-based regimens, cancers with her mutation were often resistant to standard chemotherapy. Braftovi targets pathways that allow cancer cells to reproduce and can boost effects of other therapies.
Treatment brought side effects. She became very cold-sensitive and struggled with persistent nausea. After trying many conventional anti-nausea medicines without relief, she found benefit from an oral cannabis pill at night and a CBD gummy in the morning to manage nausea and fatigue.
After eight rounds of therapy, a CT scan in October 2025 showed a complete response—no evidence of disease. The rapid and profound response surprised her doctors; such quick results were not commonly seen even in trials. Clinicians considered factors that might explain her outcome, including her age, overall fitness, and level of physical activity—she had regularly exercised and continued through treatment. Her oncologist also thought her positive attitude may have helped.
Despite the complete response on imaging, Kaiser continues to receive treatment. The V600E mutation is considered not curable and typically does not enter durable remission, so ongoing therapy is used to control disease. “They’ve never had anyone live for five years yet,” she said, noting the lack of long-term data for people living without continuous treatment.
Now 43, Kaiser balances motherhood, work, and treatment. Fatigue and reduced stamina are ongoing challenges, but a strong support network of family, friends, and neighbors helps her maintain full-time work and care for her boys. Her approach has been to plan her life first and then “fit cancer in there,” rather than allowing cancer to dictate every decision. That mindset—keeping a busy, meaningful life while managing a chronic cancer—has been central to how she copes.
Kaiser’s experience underscores the value of persistent advocacy for symptoms, the importance of molecular testing to guide targeted therapy, and the potential for innovative treatments to produce unexpectedly positive results. She continues working with the legal team of RVO Health, Healthline’s parent company.
